Menarini Group and Radius Health Announce Positive Phase III Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

The Menarini Group and Radius Health, Inc. announced positive topline results from the EMERALD study evaluating elacestrant as a monotherapy versus the standard of care for the treatment of ER+/HER2- advanced or metastatic breast cancer.